FDA drug approval summary: Erlotinib (Tarceva®) tablets

Oncologist

Volumn 10, Issue 7, 2005, Pages 461-466

  Cohen, Martin H ^a   Johnson, John R ^a   Chen, Yeh Fong ^a   Sridhara, Rajeshwari ^a   Pazdur, Richard ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Erlotinib (Tarceva ) tablets; Metastatic; Non small cell lung cancer; Second line treatment

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEMCITABINE; KETOCONAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; PACLITAXEL; PEMETREXED; PLACEBO; PLATINUM DERIVATIVE; RIFAMPICIN; TAXANE DERIVATIVE; WARFARIN;

ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORNEA ULCER; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRY SKIN; DYSPNEA; FATIGUE; FEMALE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; HUMAN; INFECTION; INTERSTITIAL LUNG DISEASE; KERATOCONJUNCTIVITIS SICCA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; REVIEW; STOMATITIS; TREATMENT OUTCOME; VOMITING;

ADENOCARCINOMA; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; DRUG APPROVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RISK FACTORS; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 24644458654     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.10-7-461     Document Type: Review

References (10)

1. Perez-Soler R. The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer. Clin Cancer Res 2004;10:4238s-4240s.
2. Herbst RS, Bunn PA Jr. Targeting the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res 2003;9:5813-5824.
3. Hidalgo M, Siu LL, Nemunaitis J et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001;19:3267-3279.
4. Gatzemeier U, Pluzanska A, Szczesna A et al. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 2004;23:617.
5. Herbst RS, Prager D, Hermann R et al. TRIBUTE - a phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 2004;23:617.
6. Perez-Soler R, Chachoua A, Huberman M et al. A phase II trial of epidermal growth factor receptor kinase inhibitor OSI-774, following platinum based chemotherapy, in patients with advanced, EGFR expressing, non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2001;20:310.
7. Bailey LR, Kris M, Wolf M et al. Tumor EGFR membrane staining is not clinically relevant for predicting response in patients receiving gefitinib (Iressa, ZD1839) monotherapy for pretreated advanced non-small cell lung cancer: IDEAL 1 and 2. Proc Am Assoc Cancer Res 2003;14:44.
8. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
9. Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500.
10. Pao W, Miller V, Zakowski M et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306-13311.